Research programme: recombinant human biglycan - Tivorsan

Drug Profile

Research programme: recombinant human biglycan - Tivorsan

Alternative Names: Biglycan; rh-BGN; TVN-102

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Brown University
  • Developer Tivorsan Pharmaceuticals
  • Class Proteoglycans
  • Mechanism of Action Utrophin activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Muscular dystrophies
  • No development reported Duchenne muscular dystrophy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral, Injection)
  • 15 Aug 2016 Recombinant human biglycan - Tivorsan receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 15 Aug 2016 Tivorsan Pharmaceuticals announces intention to submit IND application for phase I trials of recombinant human biglycan, TVN 102
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top